CHINA NT PHARMA GROUP COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.029 HKD | +3.57% |
|
+20.83% | -47.27% |
| 03-28 | China NT Pharma Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 01-15 | China NT Pharma Group Company Limited Announces Directorate Changes | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,479 | 1,199 | 280.8 | 192.4 | 110.2 | 151.4 |
| Enterprise Value (EV) 1 | 3,120 | 2,122 | 1,235 | 1,036 | 932.9 | 971.9 |
| P/E ratio | 17.4 x | -1.22 x | -0.44 x | -0.53 x | -0.73 x | -2.27 x |
| Yield | 1.83% | - | - | - | - | - |
| Capitalization / Revenue | 4.1 x | 2.1 x | 0.77 x | 0.87 x | 0.49 x | 0.73 x |
| EV / Revenue | 5.16 x | 3.71 x | 3.38 x | 4.67 x | 4.11 x | 4.69 x |
| EV / EBITDA | 10.9 x | -32.4 x | -12.7 x | -19.6 x | -17.3 x | 26.9 x |
| EV / FCF | -20.5 x | -24.6 x | 3.04 x | -1.4 x | 5.78 x | 3.95 x |
| FCF Yield | -4.88% | -4.07% | 32.9% | -71.4% | 17.3% | 25.3% |
| Price to Book | 2.27 x | 5.62 x | -1.64 x | 11.8 x | -0.52 x | -0.63 x |
| Nbr of stocks (in thousands) | 1,558,577 | 1,606,463 | 1,904,635 | 1,904,635 | 1,904,635 | 1,904,635 |
| Reference price 2 | 1.591 | 0.7464 | 0.1475 | 0.1010 | 0.0579 | 0.0795 |
| Announcement Date | 18-04-27 | 19-04-29 | 20-05-14 | 21-04-30 | 22-05-30 | 23-04-27 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 604.8 | 571.5 | 366 | 221.7 | 226.7 | 207.1 |
| EBITDA 1 | 286.9 | -65.43 | -97.2 | -52.76 | -53.79 | 36.08 |
| EBIT 1 | 255.7 | -99.36 | -125.6 | -73.03 | -89.99 | 18.92 |
| Operating Margin | 42.27% | -17.38% | -34.31% | -32.93% | -39.7% | 9.14% |
| Earnings before Tax (EBT) 1 | 226.4 | -562 | -583.5 | -200.3 | -148.8 | -54.3 |
| Net income 1 | 165.2 | -957.7 | -587.6 | -357.6 | -149.5 | -66.4 |
| Net margin | 27.31% | -167.56% | -160.56% | -161.28% | -65.96% | -32.07% |
| EPS 2 | 0.0912 | -0.6116 | -0.3331 | -0.1895 | -0.0791 | -0.0350 |
| Free Cash Flow 1 | -152.3 | -86.28 | 406.4 | -740 | 161.5 | 246.2 |
| FCF margin | -25.17% | -15.1% | 111.04% | -333.72% | 71.24% | 118.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 682.44% |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | 0.0291 | - | - | - | - | - |
| Announcement Date | 18-04-27 | 19-04-29 | 20-05-14 | 21-04-30 | 22-05-30 | 23-04-27 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 640 | 923 | 955 | 844 | 823 | 821 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.231 x | -14.1 x | -9.821 x | -15.99 x | -15.29 x | 22.74 x |
| Free Cash Flow 1 | -152 | -86.3 | 406 | -740 | 162 | 246 |
| ROE (net income / shareholders' equity) | 17.1% | -58.9% | -200% | -308% | 160% | 29.3% |
| ROA (Net income/ Total Assets) | 6% | -2.49% | -3.9% | -2.95% | -5% | 1.21% |
| Assets 1 | 2,751 | 38,454 | 15,071 | 12,118 | 2,992 | -5,507 |
| Book Value Per Share 2 | 0.7000 | 0.1300 | -0.0900 | 0.0100 | -0.1100 | -0.1300 |
| Cash Flow per Share 2 | 0.0900 | 0.0500 | 0.0100 | 0 | 0 | 0 |
| Capex 1 | 9.73 | 11.9 | 36 | 23.8 | 0.65 | 4.49 |
| Capex / Sales | 1.61% | 2.09% | 9.85% | 10.75% | 0.28% | 2.17% |
| Announcement Date | 18-04-27 | 19-04-29 | 20-05-14 | 21-04-30 | 22-05-30 | 23-04-27 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -47.27% | 9.45M | |
| +21.08% | 43.18B | |
| +20.67% | 22.59B | |
| +15.11% | 14.56B | |
| +38.77% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B | |
| -2.27% | 4.81B |
- Stock Market
- Equities
- 1011 Stock
- Financials China NT Pharma Group Company Limited
